Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

AccuVein Vein Illuminator Receives European CE Mark
AccuVein LLC, maker of the AV300, the world"s first hand-held, non-contact vein illumination device, announced today that its medical device now carries a CE Mark, enabling the Company to commence European sales of AccuVein"s AV300.
generic viagra online
Teeth And Gums Also Benefit From The Healing Power Of Aloe Vera
The aloe vera plant has a long history of healing power. Its ability to heal burns and cuts and soothe pain has been documented as far back as the 10th century. Legend has it that Cleopatra used aloe vera to keep her skin soft. The modern use of aloe vera was first recognized the 1930s to heal radiation burns. Since then, it has been a common ingredient in ointments that heal sunburn, minor cuts, skin irritation, and many other ailments. Recently, aloe vera has gained some popularity as an active ingredient in tooth gel. Similar to its use on skin, the aloe vera in tooth gels is used to cleanse and soothe teeth and gums, and is as effective as toothpaste to fight cavities, according to the May/June 2009 issue of General Dentistry, the Academy of General Dentistry"s (AGD) clinical, peer-reviewed journal.
News of the day
AdvanDx Receives FDA 510(k) Clearance For GBS PNA FISH(R) For Rapid Detection Of Group B Strep From Lim Broths
AdvanDx announced it received FDA 510(k) clearance for GBS PNA FISH(R) for detection of Streptococcus agalactiae, aka Group B Strep, from turbid Lim Broths inoculated with vaginal and rectal swabs obtained from pregnant women between 35 and 37 weeks gestation. The 90 minute molecular diagnostic test enables rapid and highly sensitive detection of Group B Strep from Lim Broths to help detect colonization in pregnant women.
Endocrinology

Novartis To Partner With OneWorld Health To Develop Diarrhea Drug

"Swiss drug company Novartis AG and the Institute for OneWorld Health, a nonprofit group, will announce this week a partnership to discover drugs for a type of diarrhea that kills about 1.6 million children each year in the developing world," the Wall Street Journal reports. Though fluid treatments to prevent dehydration have helped "sharply cut the number of deaths" from secretory diarrhea in recent years "additional treatments are desperately needed, Richard Chin, chief executive of OneWorld Health, said in a phone interview," the newspaper writes. As part of the partnership, ten Novartis scientists will first sift through drugs candidates, before "pass[ing] along any promising candidates to OneWorld Health for further testing." The newspaper writes: "OneWorld Health, based in San Francisco, has been working on secretory diarrhea since 2006, using a $47 million grant from the Bill and Melinda Gates Foundation. The group already has a research partnership with Swiss drug company Roche Holding AG, which has allowed the nonprofit group to scan Roche"s library of experimental drugs for candidates that might work against diarrhea" (Whalen, 7/14). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009